R25HG013004

Great: Collaborative genomic initiative between Prairie View A&M and Texas A&M universities.

Prairie View A&M University

AS A LEADING AUTHORITY IN THE FIELD OF GENOMICS, THE MISSION OF THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI) IS TO ACCELERATE SCIENTIFIC AND MEDICAL BREAKTHROUGHS THAT IMPROVE HUMAN HEALTH BY DRIVING CUTTING-EDGE RESEARCH, DEVELOPING NEW TECHNOLOGIES, AND STUDYING THE IMPACT OF GENOMICS ON SOCIETY. CONGRESS INITIALLY ESTABLISHED NHGRI TO CHARACTERIZE THE STRUCTURE AND FUNCTION OF THE HUMAN GENOME, INCLUDING THE MAPPING AND SEQUENCING OF INDIVIDUAL GENES. THIS ALSO INCLUDES REVIEWING AND FUNDING RESEARCH PROPOSALS, DEVELOPING TRAINING PROGRAMS, COORDINATING INTERNATIONAL GENOME RESEARCH, COMMUNICATING ADVANCES IN GENOME SCIENCE TO THE PUBLIC, AND REVIEWING AND FUNDING PROPOSALS TO ADDRESS THE ETHICAL AND LEGAL ISSUES ASSOCIATED WITH THIS RESEARCH.NHGRI SUPPORTS THE DEVELOPMENT OF METHODS, RESOURCES AND TECHNOLOGIES TO IMPROVE THE HEALTH OF ALL HUMANS THROUGH ADVANCES IN GENOMICS RESEARCH. NHGRI SUPPORTS RESEARCH THAT ACCELERATES FOUNDATIONAL RESOURCES, TECHNOLOGY DEVELOPMENT, AND EXPERIMENTAL AND COMPUTATIONAL APPROACHES FOR BASIC GENOMICS AND FUNCTIONAL GENOMICS RESEARCH; FOR THE APPLICATION OF GENOMICS TO MEDICAL SCIENCE AND CLINICAL CARE; AND TO SUPPORT ETHICAL, LEGAL AND SOCIAL IMPLICATIONS (ELSI) RESEARCH CONCERNING SOCIETAL ISSUES THAT NEED TO BE ADDRESSED, ESPECIALLY AS GENOMIC SCIENCE ADVANCES. FOR YEARS, NHGRI HAS PARTICIPATED IN THE NIH EFFORT TO TURN DISCOVERY INTO HEALTH BY HELPING SMALL BUSINESSES DEVELOP INNOVATIVE GENOMICS TECHNOLOGIES THAT IMPROVE HEALTH AND SAVE LIVES. NHGRI ALSO DEVELOPS AND SUPPORTS INITIATIVES THAT EXPAND OPPORTUNITIES FOR GENOMICS EDUCATION AND CAREERS, CULTIVATING GENOMICS TRAINING PROGRAMS AND WORKFORCE DEVELOPMENT INITIATIVES.

93.172 - Human Genome Research

National Human Genome Research Institute (NHGRI) [HHS - NIH]

Hempstead, Texas 774456850 United States

Single Zip Code

Genome Research Experiences to Attract Talented Undergraduates into Genomic Fields to Enhance Diversity (R25 Clinical Trial Not Allowed) (RFA-HG-22-004)

Amendment Since initial award the End Date has been extended from 07/31/28 to 01/31/29 and the total obligations have increased 199% from $380,000 to $1,136,000.